Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

Dialysis

ESA responsiveness and outcomes in patients on hemodialysis

Nature Reviews Nephrology volume 8, pages 6–8 (2012)Cite this article

Subjects

Whether erythropoiesis-stimulating agents (ESAs) administered in high doses could be harmful is a subject of intense interest. A recent trial has studied the relationship between hemoglobin level, ESA dose and outcomes in Japanese patients on hemodialysis. Here, we review the findings and the possible impact on clinical anemia treatment.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Association between 12 categories of ESA responsiveness and mortality for all-cause and cardiovascular disease in Fukuma et al.'s study.

References

  1. Fukuma, S. et al. Erythropoiesis-stimulating agent responsiveness and mortality in hemodialysis patients: results from a cohort study from the Dialysis Registry in Japan. Am. J. Kidney Dis. http://dx.doi.org/10.1053/j.ajkd.2011.07.014.

  2. Pfeffer, M. A. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019–2032 (2009).

    Article  Google Scholar 

  3. Phrommintikul, A., Haas, S. J., Elsik, M. & Krum, H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369, 381–388 (2007).

    Article  CAS  Google Scholar 

  4. Pfeffer, M. A. et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N. Engl. J. Med. 361, 2019–2032 (2009).

    Article  Google Scholar 

  5. Ma, J. Z., Ebben, J., Xia, H. & Collins, A. J. Hematocrit level and associated mortality in hemodialysis patients. J. Am. Soc. Nephrol. 10, 610–619 (1999).

    CAS  Google Scholar 

  6. Zhang, Y., Thamer, M., Stefanik, K., Kaufman, J. & Cotter, D. J. Epoetin requirements predict mortality in hemodialysis patients. Am. J. Kidney Dis. 44, 866–876 (2004).

    Article  CAS  Google Scholar 

  7. Macdougall, I. C. Recent advances in erythropoietic agents in renal anemia. Semin. Nephrol. 26, 313–318 (2006).

    Article  Google Scholar 

  8. Strippoli, G. F. et al. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C. E. DOSE) trial protocol. Trials 11, 70 (2010).

    Article  Google Scholar 

  9. Fishbane, S. Recombinant human erythropoietin: has treatment reached its full potential? Semin. Dial. 19, 1–4 (2006).

    Article  Google Scholar 

  10. US Department of Health & Human Services. FDA Drug Safety Communication: Modified dosing recommendations to improve the safe use of erythropoiesis-stimulating agents (ESAs) in chronic kidney disease. US Food and Drug Administration [online], (2011).

Download references

Author information

Authors and Affiliations

  1. Division of Kidney Diseases and Hypertension, Department of Medicine, North Shore University Hospital and Long Island Jewish Medical Center, North Shore-Long Island Jewish (LIJ) Health System, Hofstra North Shore-LIJ School of Medicine, Great Neck, 11021, New York, USA

    Steven Fishbane & Azzour Hazzan

Authors
  1. Steven Fishbane
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Azzour Hazzan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Steven Fishbane.

Ethics declarations

Competing interests

S. Fishbane declares associations with the following companies: Affymax (consultant), Akebia (consultant), Bayer (consultant), Rockwell (consultant). A. Hazzan declares no competing interests.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fishbane, S., Hazzan, A. ESA responsiveness and outcomes in patients on hemodialysis. Nat Rev Nephrol 8, 6–8 (2012). https://doi.org/10.1038/nrneph.2011.169

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrneph.2011.169

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing